In last trading session, Adma Biologics Inc (NASDAQ:ADMA) saw 4.18 million shares changing hands with its beta currently measuring 0.48. Company’s recent per share price level of $19.47 trading at -$0.41 or -2.06% at ring of the bell on the day assigns it a market valuation of $4.65B. That closing price of ADMA’s stock is at a discount of -31.84% from its 52-week high price of $25.67 and is indicating a premium of 55.06% from its 52-week low price of $8.75. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.54 million shares which gives us an average trading volume of 3.65 million if we extend that period to 3-months.
For Adma Biologics Inc (ADMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.14 in the current quarter.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Upright in the red during last session for losing -2.06%, in the last five days ADMA remained trading in the red while hitting it’s week-highest on Thursday, 05/08/25 when the stock touched $19.47 price level, adding 14.34% to its value on the day. Adma Biologics Inc’s shares saw a change of 13.53% in year-to-date performance and have moved -17.53% in past 5-day. Adma Biologics Inc (NASDAQ:ADMA) showed a performance of -6.89% in past 30-days. Number of shares sold short was 12.35 million shares which calculate 3.09 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a fall of -21.69% to its current value. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would jump 28.09% in reaching the projected high whereas dropping to the targeted low would mean a gain of 28.09% for stock’s current value.
Adma Biologics Inc (ADMA) estimates and forecasts
This year revenue growth is estimated to rise 19.90% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 124.13M for the same. And 3 analysts are in estimates of company making revenue of 133.4M in the next quarter. Company posted 107.19M and 119.84M of sales in current and next quarters respectively a year earlier.
In 2025, company’s earnings growth rate is likely to be around 31.94% while estimates for its earnings growth in next 5 years are of 39.25%.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders are in possession of 2.59% of company’s total shares while institution are holding 562.34 percent of that, with stock having share float percentage of 577.28%. Investors also watch the number of corporate investors in a company very closely, which is 562.34% institutions for Adma Biologics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ADMA for having 18.64 million shares of worth $208.45 million. And as of 2024-06-30, it was holding 8.0221 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 14.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.2459 of outstanding shares, having a total worth of $162.3 million.
On the other hand, iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 14.62 shares of worth $284.6 million or 6.12% of the total outstanding shares. The later fund manager was in possession of 7.0 shares on Dec 31, 2024 , making its stake of worth around $136.32 million in the company or a holder of 2.93% of company’s stock.
